PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
43.33%
Net income growth above 1.5x AGEN's 27.86%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-26.41%
Both reduce yoy D&A, with AGEN at -21.14%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
-627.56%
Negative yoy deferred tax while AGEN stands at 4389.28%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
174.63%
SBC growth well above AGEN's 53.62%. Michael Burry would flag major dilution risk vs. competitor’s approach.
-214.26%
Negative yoy working capital usage while AGEN is 2835.06%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-295.13%
Negative yoy AP while AGEN is 2903.31%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-30.84%
Negative yoy usage while AGEN is 3355.84%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
848.72%
Some yoy increase while AGEN is negative at -49.55%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-15.17%
Negative yoy CFO while AGEN is 131.36%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
100.00%
CapEx growth well above AGEN's 81.13%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Less 'other investing' outflow yoy vs. AGEN's 147638.22%. David Dodd would see a stronger short-term cash position unless competitor invests more wisely.
100.00%
Lower net investing outflow yoy vs. AGEN's 933.75%, preserving short-term cash. David Dodd would confirm expansions remain sufficient.
-2235.51%
Both yoy lines negative, with AGEN at -880.00%. Martin Whitman suspects an environment prompting net new borrowings or weaker paydowns across the niche.
219.76%
Issuance growth of 219.76% while AGEN is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.